ENDRA Life Sciences (NDRA) Capital Expenditures (2018 - 2025)

ENDRA Life Sciences has disclosed Capital Expenditures across 8 years of filings, most recently posting $17280.0 for Q1 2025.

• In Q1 2025, Capital Expenditures fell 36.0% year-over-year to $17280.0; the TTM figure through Dec 2025 stood at $17280.0 (up 8.0% YoY), while the FY2025 annual figure was $17280.0, up 8.0% from the prior year.
• Capital Expenditures advanced to $17280.0 in Q1 2025, from -$11000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for NDRA reached as high as $89353.0 in Q1 2022 and fell as low as -$11000.0 in Q2 2024.
• The 5-year median for Capital Expenditures is $27000.0 (2023), against an average of $31474.1.
• Annual changes were most pronounced in 2021 — Capital Expenditures soared 101.34% — and 2023, when it tumbled 82.15%.
• A 5-year view of Capital Expenditures shows it stood at $45000.0 in 2021, then retreated by 14.3% to $38563.0 in 2022, then plunged by 82.15% to $6884.0 in 2023, then plunged by 259.79% to -$11000.0 in 2024, then surged by 257.09% to $17280.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $17280.0, -$11000.0, and $27000.0 for Q1 2025, Q2 2024, and Q1 2024 respectively.